Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 2
2014 4
2015 2
2016 4
2017 3
2019 1
2021 3
2022 3
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, Janssen JJWM, Mahon FX, Minami Y, Yeung D, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan Y, Meille C, Hourcade-Potelleret F, Vanasse KG, Lang F, Kim DW. Hughes TP, et al. Among authors: meille c. N Engl J Med. 2019 Dec 12;381(24):2315-2326. doi: 10.1056/NEJMoa1902328. N Engl J Med. 2019. PMID: 31826340 Free PMC article. Clinical Trial.
Metronomics chemotherapy: time for computational decision support.
Barbolosi D, Ciccolini J, Meille C, Elharrar X, Faivre C, Lacarelle B, André N, Barlesi F. Barbolosi D, et al. Among authors: meille c. Cancer Chemother Pharmacol. 2014 Sep;74(3):647-52. doi: 10.1007/s00280-014-2546-1. Epub 2014 Aug 1. Cancer Chemother Pharmacol. 2014. PMID: 25082520 Review.
Taxanes in paediatric oncology: and now?
André N, Meille C. André N, et al. Among authors: meille c. Cancer Treat Rev. 2006 Apr;32(2):65-73. doi: 10.1016/j.ctrv.2005.12.010. Epub 2006 Feb 23. Cancer Treat Rev. 2006. PMID: 16497442 Review.
A framework to guide dose & regimen strategy for clinical drug development.
Sander O, Magnusson B, Ludwig I, Jullion A, Meille C, Lorand D, Bornkamp B, Hinder M, Kovacs SJ, Looby M. Sander O, et al. Among authors: meille c. CPT Pharmacometrics Syst Pharmacol. 2021 Nov;10(11):1276-1280. doi: 10.1002/psp4.12701. Epub 2021 Sep 25. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34562310 Free PMC article.
Contribution of machine learning to tumor growth inhibition modeling for hepatocellular carcinoma patients under Roblitinib (FGF401) drug treatment.
Wilbaux M, Demanse D, Gu Y, Jullion A, Myers A, Katsanou V, Meille C. Wilbaux M, et al. Among authors: meille c. CPT Pharmacometrics Syst Pharmacol. 2022 Aug;11(8):1122-1134. doi: 10.1002/psp4.12831. Epub 2022 Jun 21. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 35728123 Free PMC article. Clinical Trial.
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia.
Stein EM, DeAngelo DJ, Chromik J, Chatterjee M, Bauer S, Lin CC, Suarez C, de Vos F, Steeghs N, Cassier PA, Tai D, Kiladjian JJ, Yamamoto N, Mous R, Esteve J, Minami H, Ferretti S, Guerreiro N, Meille C, Radhakrishnan R, Pereira B, Mariconti L, Halilovic E, Fabre C, Carpio C. Stein EM, et al. Among authors: meille c. Clin Cancer Res. 2022 Mar 1;28(5):870-881. doi: 10.1158/1078-0432.CCR-21-1295. Clin Cancer Res. 2022. PMID: 34862243 Free PMC article. Clinical Trial.
Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies.
Bauer S, Demetri GD, Halilovic E, Dummer R, Meille C, Tan DSW, Guerreiro N, Jullion A, Ferretti S, Jeay S, Van Bree L, Hourcade-Potelleret F, Wuerthner JU, Fabre C, Cassier PA. Bauer S, et al. Among authors: meille c. Br J Cancer. 2021 Aug;125(5):687-698. doi: 10.1038/s41416-021-01444-4. Epub 2021 Jun 17. Br J Cancer. 2021. PMID: 34140638 Free PMC article. Clinical Trial.
23 results